Impact on hospitalization and infection patterns of advanced lung cancer with lower respiratory tract infections: Targeted therapy vs. chemoradiotherapy

Zhang,Dan; Jin,Jingjing; Dou,Jianying; Huang,Yan; Zhang,Haibo

doi:10.3892/ol.2024.14287

Impact on hospitalization and infection patterns of advanced lung cancer with lower respiratory tract infections: Targeted therapy vs. chemoradiotherapy

Authors:
- Dan Zhang
- Jingjing Jin
- Jianying Dou
- Yan Huang
- Haibo Zhang
View Affiliations

Affiliations: Department of Respiratory Medicine, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei 063000, P.R. China, Keenan Research Centre for Biomedical Science of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, ON M5B1T8, Canada
Published online on: February 14, 2024 https://doi.org/10.3892/ol.2024.14287
Article Number: 154
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is a prevalent and highly lethal disease often complicated by lower respiratory tract infections. Microbial patterns in these infections vary based on treatment modalities. The present study explored the impact of lung cancer treatments on pathogens and clinical characteristics in the presence of lower respiratory tract infections to inform antimicrobial drug selection. A retrospective analysis was performed that included data from 93 patients diagnosed with advanced lung cancer and lower respiratory tract infections between January 2019 and December 2021. Patients were divided into the targeted therapy and chemoradiotherapy groups. Clinical, nutritional, biochemical, infection and pathogenetic indicators were compared. Of the 93 cases, 24 were in the targeted therapy group and 69 were in the chemoradiotherapy group. Pathological type and hospitalization duration differed significantly (P<0.05), but age, sex, smoking history, alcohol consumption and underlying diseases did not (P>0.05). Lymphocyte counts differed (P<0.05), while body mass index, albumin, hemoglobin, alanine aminotransferase and creatinine levels, erythrocyte sedimentation rate, hypersensitive C‑reactive protein and procalcitonin levels, and the percentage of neutrophils did not (P>0.05). Pathogenetic testing was negative in 15 patients and positive in 78 patients, with Gram‑negative bacteria (61.77%), fungi (17.65%) and viruses (11.76%) predominant in the targeted therapy group. In the chemoradiotherapy group, Gram‑negative bacteria (47.46%), fungi (28.81%) and viruses (16.95%) were also more prevalent. Candida albicans was the most frequent fungal infection in both groups, and mixed infections were common (50% in targeted therapy and 73.92% in chemoradiotherapy). The chemoradiotherapy group had significantly more mixed infections (P<0.05). Overall, common pathogens in both groups included Gram‑negative bacteria, fungi and viruses. Chemoradiotherapy patients experienced longer hospital stays and a higher incidence of mixed infections, predominantly involving Gram‑negative bacteria and fungi. The results provide valuable insights into the rational selection of empirical antibiotics and antifungals for critically ill patients with lung cancer and lower respiratory tract infections in targeted therapy or chemoradiotherapy.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Rolston KV: Infections in cancer patients with solid tumors: A review. Infect Dis Ther. 6:69–83. 2017. View Article : Google Scholar : PubMed/NCBI
3	Honda Y: Lung cancer and respiratory infections. Gan To Kagaku Ryoho. 47:750–753. 2020.(In Japanese). PubMed/NCBI
4	Patel B and Priefer R: Impact of chronic obstructive pulmonary disease, lung infection, and/or inhaled corticosteroids use on potential risk of lung cancer. Life Sci. 294:1203742022. View Article : Google Scholar : PubMed/NCBI
5	Alexander M, Kim SY and Cheng H: Update 2020: Management of non-small cell lung cancer. Lung. 198:897–907. 2020. View Article : Google Scholar : PubMed/NCBI
6	Vento S, Cainelli F and Temesgen Z: Lung infections after cancer chemotherapy. Lancet Oncol. 9:982–992. 2008. View Article : Google Scholar : PubMed/NCBI
7	Guckenberger M, Belka C, Bezjak A, Bradley J, Daly ME, DeRuysscher D, Dziadziuszko R, Faivre-Finn C, Flentje M, Gore E, et al: Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiother Oncol. 146:223–229. 2020. View Article : Google Scholar : PubMed/NCBI
8	Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, et al: The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
9	Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gilligan PH, Gonzalez MD, Jerris RC, Kehl SC, Patel R, et al: A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis. 67:e1–e94. 2018. View Article : Google Scholar : PubMed/NCBI
10	Travis WD, Brambilla E, Burke AP, Marx A and Nicholson AG: Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
11	Reinmuth N and Hoffmann H: Small Cell Lung Cancer. TumorDiagnostik & Therapie. 43:307–320. 2022.(In German).
12	Zhong J, Bai H, Wang Z, Duan J, Zhuang W, Wang D, Wan R, Xu J, Fei K, Ma Z, et al: Treatment of advanced non-small cell lung cancer with driver mutations: Current applications and future directions. Front Med. 17:18–42. 2023. View Article : Google Scholar : PubMed/NCBI
13	Iijima Y, Bandow K, Sano M, Hino S, Kaneko T, Horie N and Sakagami H: In vitro assessment of antitumor potential and combination effect of classical and molecular-targeted anticancer drugs. Anticancer Res. 39:6673–6684. 2019. View Article : Google Scholar : PubMed/NCBI
14	Piperdi B, Merla A and Perez-Soler R: Targeting angiogenesis in squamous non-small cell lung cancer. Drugs. 74:403–413. 2014. View Article : Google Scholar : PubMed/NCBI
15	Kamba T and McDonald D: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 96:1788–1795. 2007. View Article : Google Scholar : PubMed/NCBI
16	Zappa C and Mousa SA: Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
17	Uzel EK, Figen M and Uzel Ö: Radiotherapy in lung cancer: Current and future role. Sisli Etfal Hastan Tip Bul. 53:353–360. 2019.PubMed/NCBI
18	Howlader N, Noone A, Krapcho Me, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, et al: SEER cancer statistics review, 1975–2016. National Cancer Institute; Bethesda, MD: 2019, https://seer.cancer.gov/csr/1975_2016/September 18–2023
19	Chen W, Zhong S, Shan B, Zhou S, Wu X, Yang H and Ye S: Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications. J Ovarian Res. 13:892020. View Article : Google Scholar : PubMed/NCBI
20	Dunn GP, Old LJ and Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21:137–148. 2004. View Article : Google Scholar : PubMed/NCBI
21	Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, et al: Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71:768–778. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kadakia KC, Symanowski JT, Aktas A, Szafranski ML, Salo JC, Meadors PL and Walsh D: Malnutrition risk at solid tumor diagnosis: The malnutrition screening tool in a large US cancer institute. Support Care Cancer. 30:2237–2244. 2022. View Article : Google Scholar : PubMed/NCBI
23	Mozaffari F, Lindemalm C, Choudhury A, Granstam-Björneklett H, Helander I, Lekander M, Mikaelsson E, Nilsson B, Ojutkangas ML, Osterborg A, et al: NK-cell and T-cell functions in patients with breast cancer: Effects of surgery and adjuvant chemo-and radiotherapy. Br J Cancer. 97:105–111. 2007. View Article : Google Scholar : PubMed/NCBI
24	Sun XY, Lin Y, Guo W and Yin XM: Prognostic value of the geriatric nutritional risk index in patients with non-small cell lung cancer: A meta-analysis. Nutr Cancer. 74:3623–3633. 2022. View Article : Google Scholar : PubMed/NCBI
25	Worku M, Belay G and Tigabu A: Bacterial profile and antimicrobial susceptibility patterns in cancer patients. PLoS One. 17:e02669192022. View Article : Google Scholar : PubMed/NCBI
26	Mei T, Yang X, Yu Y, Tian X, Deng Q, Xu Y, Zhou L, Zhou X, Liu Y, Zou B, et al: Secondary infections after diagnosis of Severe Radiation Pneumonitis (SRP) among patients with non-small cell lung cancer: Pathogen distributions, choice of empirical antibiotics, and the value of empirical antifungal treatment. Int J Radiat Oncol Biol Phys. 112:179–187. 2022. View Article : Google Scholar : PubMed/NCBI
27	Freire MP, de Oliveira Garcia D, Garcia CP, Campagnari Bueno MF, Camargo CH, Kono Magri ASG, Francisco GR, Reghini R, Vieira MF, Ibrahim KY, et al: Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: High mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect. 22:352–358. 2016. View Article : Google Scholar : PubMed/NCBI
28	Zhu Z and Zou X: Analysis of factors for susceptibility to a pulmonary fungal infection in elderly patients with lung cancer and the drug resistance of those fungi. J Pathog Biol. 3:633–636. 2018.(In Chinese).
29	Wilson O and Flahault A: China's U-turn in its COVID-19 policy. Anaesth Crit Care Pain Med. 42:1011972023. View Article : Google Scholar : PubMed/NCBI
30	Du Z, Wang Y, Bai Y, Wang L, Cowling BJ and Meyers LA: Estimate of COVID-19 Deaths, China, December 2022-February 2023. Emerg Infect Dis. 29:2121–2124. 2023. View Article : Google Scholar : PubMed/NCBI
31	Qiao D, Wang Z, Lu Y, Wen X, Li H and Zhao H: A retrospective study of risk and prognostic factors in relation to lower respiratory tract infection in elderly lung cancer patients. Am J Cancer Res. 5:423–432. 2015.PubMed/NCBI
32	Yu K, Sang QA, Lung PY, Tan W, Lively T, Sheffield C, Bou-Dargham MJ, Liu JS and Zhang J: Personalized chemotherapy selection for breast cancer using gene expression profiles. Sci Rep. 7:432942017. View Article : Google Scholar : PubMed/NCBI